在儿科炎症性肠病中与药物相关的不良反应
Ana Losa1, Rita Gomes1, Francisco Ribeiro Mourão2
1Pediatrics Department, Centro Materno Infantil do Norte Albino Aroso, Centro Hospitalar Universitário de Santo António (CMIN-CHUdSA), Porto, Portugal.
副作用发生在16.2%的儿科炎性肠病 (IBD) 患者中,其中阿扎西奥普林最常见. 虽然大多数是轻微的,但这些AR通常需要改变治疗方法,影响疾病管理.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 药物监督 药物监督 药物监督
- 炎症性肠病 (IBD) 的治疗方法
背景情况:
- 儿童的炎症性肠病 (IBD) 管理是复杂的,通常需要多种药物.
- 了解与药物相关的不良反应 (AR) 对于优化儿科IBD治疗至关重要.
研究的目的:
- 为了确定与药物相关的不良反应 (ARs) 的发生率和特征,在儿科患者IBD.
- 为了确定特定的药物和反应类型最常见的与ARs在这个人群中相关.
主要方法:
- 在第三级医院对99名儿科IBD患者 (2010-2022) 的回顾性研究.
- 分析包括免疫调节剂,肠道营养和生物制剂在内的疗法.
- 评估AR发病率,药物参与和结果.
主要成果:
- 16.2%的患者经历了AR,其中阿扎西奥普林是涉及最多的药物 (75%).
- 肝炎是最常见的AR (31.3%),通常需要停止治疗.
- 在处方药的数量和AR发生率 (P=.044) 之间发现了积极的关联.
结论:
- 与药物相关的AR是儿科IBD的一个重大问题,影响了治疗的连续性.
- 虽然AR通常是轻微的,但需要仔细监测,并可能影响长期的疾病控制.
- 对儿童IBD更安全的治疗策略进行进一步的研究是有必要的.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
